Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies

View ORCID ProfileMichael P Hengartner, Simone Amendola, Jakob A Kaminski, Simone Kindler, Tom Bschor, Martin Plöderl
doi: https://doi.org/10.1101/2020.05.11.20098178
Michael P Hengartner
1Department of Applied Psychology, Zurich University of Applied Sciences, CH-8037 Zurich, Switzerland,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Michael P Hengartner
  • For correspondence: heng{at}zhaw.ch
Simone Amendola
2Department of Dynamic and Clinical Psychology, Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Roma RM, Italy,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jakob A Kaminski
3Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simone Kindler
4Psychotherapist in private practice, CH-8400 Winterthur, Switzerland,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom Bschor
5Department of Psychiatry and Psychotherapy, University Hospital, Technical University of Dresden, 01069 Dresden, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Plöderl
6Department of Crisis Intervention and Suicide Prevention, Christian Doppler Clinic, Paracelsus Medical University Salzburg, 5020 Salzburg, Austria
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Background There is ongoing controversy whether antidepressant use alters the suicide risk in adult routine-care patients with depression and other treatment indications. The aim of this study was thus to examine the suicide risk with antidepressants in observational studies, considering financial conflicts of interest (fCOI) and publication bias.

Design Systematic review and meta-analysis.

Main outcome measures Risk of suicide, suicide attempt and/or intentional self-harm.

Data sources We searched MEDLINE, PsycINFO, Web of Science, PsycARTICLES and SCOPUS for case-control and cohort studies published 1990-2020.

Eligibility criteria for study selection Cohort and case-control studies in adults (aged ≥18 years) with depression and any unspecified condition reporting suicide risk for patients exposed to selective serotonin reuptake inhibitors (SSRI) or new-generation serotonergic-noradrenergic antidepressants (SNA) relative to unexposed patients.

Data extraction and analysis Effects were aggregated with a random-effects model and reported as relative risk estimates (RE) with 95%-confidence-intervals. We assessed heterogeneity via I2-statistics and publication bias via funnel-plot asymmetry and trim-and-fill method. Study fCOI was defined present when lead-authors’ professorship was industry-sponsored, they received payments from the industry, or when the study was industry-sponsored.

Results We included 27 original studies in the meta-analysis; 19 on depression (including other affective and anxiety disorders) and 8 on any unspecified condition. Use of SSRI or SNA for depression was associated with increased suicide risk (comprising both suicide and suicide attempt), RE=1.29, 1.06-1.57. Risk estimates were significantly lower in studies with fCOI (Q=21.87, p<0.001) and the trim-and-fill method estimated that 12 studies were missing due to publication bias; the result with missing studies imputed was RE=1.61, 1.31-1.99. Use of SSRI or SNA for all conditions (including depression and any unspecified condition) was associated with increased suicide risk, RE=1.43, 1.21-1.68. Studies with fCOI reported significantly lower risk estimates (Q=34.19, p<0.001) and the trim-fill method estimated that 13 studies were missing; after imputation of missing studies the result was RE=1.72, 1.44-2.05. Quality of evidence was rated very low due to substantial inconsistency of between-study results (I2≥85%).

Conclusions Exposure to new-generation antidepressants is associated with increased suicide risk in adult routine-care patients with depression and other conditions. Publication bias and fCOI contribute to systematic underestimation of risk estimates in the published literature.

Registration Open Science Framework, https://osf.io/eaqwn/

What is already known on this topic Meta-analyses of randomised controlled trials (RCT) found either no reduction of suicidal events or increased risk with new-generation antidepressants relative to placebo. However, generalisability of RCT findings is limited due to narrowly preselected participants, short study duration and treatment settings that are not representative of primary care routine practice. A previous meta-analysis of observational studies reported significantly reduced suicide risk in adults with depression exposed to selective serotonin reuptake inhibitors (SSRI), but it did not include new-generation serotonergic-noradrenergic antidepressants (SNA) and did not consider publication bias and study lead-authors’ financial conflicts of interest (fCOI).

What this study adds Our results indicate that SSRI and SNA are associated with increased suicide risk in adult routine-care patients with depression and other psychiatric and non-psychiatric treatment indications. We further found empirical evidence for publication bias. Several studies with evidence of increased suicide risk with new-generation antidepressants likely remain unpublished. Accordingly, we found that study lead-authors with fCOI report significantly lower risk estimates than lead-authors without fCOI.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Protocols

https://osf.io/eaqwn/

Funding Statement

No funding was received for this particular study

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data and statistical code will be made freely available upon publication of the study in a scientific journal

https://osf.io/eaqwn/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted May 19, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies
Michael P Hengartner, Simone Amendola, Jakob A Kaminski, Simone Kindler, Tom Bschor, Martin Plöderl
medRxiv 2020.05.11.20098178; doi: https://doi.org/10.1101/2020.05.11.20098178
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Suicide risk with selective serotonin reuptake inhibitors and new-generation serotonergic-noradrenergic antidepressants in adults: a systematic review and meta-analysis of observational studies
Michael P Hengartner, Simone Amendola, Jakob A Kaminski, Simone Kindler, Tom Bschor, Martin Plöderl
medRxiv 2020.05.11.20098178; doi: https://doi.org/10.1101/2020.05.11.20098178

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)